Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa
Authors:
Open Access
- 1 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 136 (6) , 881-888
Abstract
We evaluated HER2 expression profiles in 32 carcinoma in situ (CIS) and 31 non-CIS conditions (5 dysplasia and 26 reactive atypia) of the urinary bladder mucosa by applying breast cancer scoring rules. In situ hybridization was performed on tissue microarrays to assess HER2 gene amplification status. Our immunoprofiling data disclosed moderate to strong HER2 expression in CIS, including the basal layer of the urothelium, and absent to weak HER2 expression in non-CIS conditions. From the histologic differential diagnostic standpoint, immunostaining for HER2 protein represents a useful adjunct to aid in the delineation between CIS and non-CIS conditions of the bladder mucosa. Pathogenically, aberrant HER2 protein expression in CIS seems to be more commonly associated with polysomy than with gene amplification. From a therapeutic viewpoint, prospective clinical studies should investigate the potential benefit of HER2-targeted therapies in CIS, particularly in cases unresponsive to conventional therapeutic regimens.Keywords
This publication has 24 references indexed in Scilit:
- Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully ExploitedEuropean Urology, 2011
- Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patientsAnnals of Oncology, 2009
- HER2Overexpression and Amplification in Urothelial Carcinoma of the Bladder Is Associated WithMYCCoamplification in a Subset of CasesAmerican Journal of Clinical Pathology, 2008
- HER2 testing in the UK: further update to recommendationsJournal of Clinical Pathology, 2008
- Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesionsJournal of Clinical Pathology, 2007
- Novel Approach of Human Epidermal Growth Factor Receptor 2 Detection in Noninvasive and Invasive Transitional Cell Carcinoma of the BladderJournal of Urology, 2006
- Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testingJournal of Clinical Pathology, 2004
- Urinary bladder biopsy with denuded mucosa: Denuding cystitis—Cytopathologic correlatesDiagnostic Cytopathology, 2004
- HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?European Journal of Cancer, 2004
- Bladder CancerEuropean Urology, 2001